BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verhestraeten C, Heggermont WA, Maris M. Clinical inertia in the treatment of heart failure: a major issue to tackle. Heart Fail Rev 2020. [PMID: 32474794 DOI: 10.1007/s10741-020-09979-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Horiguchi D, Shin S, Pepino JA, Peterson JT, Kehoe IE, Goldstein JN, Mcauley ME, Lee J, Lux LR, Kwon BK, Hahn J, Reisner AT. Hypotension During Vasopressor Infusion Occurs in Predictable Clusters: A Multicenter Analysis.. [DOI: 10.1101/2022.08.25.22279077] [Reference Citation Analysis]
2 Cotter JM, Florin TA, Moss A, Suresh K, Ramgopal S, Navanandan N, Shah SS, Ruddy RM, Ambroggio L. Factors Associated With Antibiotic Use for Children Hospitalized With Pneumonia. Pediatrics 2022;150:e2021054677. [PMID: 35775330 DOI: 10.1542/peds.2021-054677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ilonze O, Free K, Breathett K. Unequitable Heart Failure Therapy for Black, Hispanic and American-Indian Patients. Card Fail Rev 2022;8:e25. [DOI: 10.15420/cfr.2022.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Almufleh A, Turgeon RD, Ducharme A, Billia F, Ezekowitz J. Proposal for an Ambulatory Heart Failure Management Curriculum for Cardiology Residency Training Programs. CJC Open 2022. [DOI: 10.1016/j.cjco.2022.07.005] [Reference Citation Analysis]
5 Liu A, Zhang Y, Xun S, Zhou G, Lin L, Mei Y. Fibroblast growth factor 12 attenuated cardiac remodeling via suppressing oxidative stress. Peptides 2022;:170786. [PMID: 35304156 DOI: 10.1016/j.peptides.2022.170786] [Reference Citation Analysis]
6 Ariss RW, Gupta R. Estimated Aggregate Treatment Benefit With Addition of Multiple Novel Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease. J Cardiovasc Pharmacol Ther 2022;27:10742484221084772. [PMID: 35259008 DOI: 10.1177/10742484221084772] [Reference Citation Analysis]
7 Gilyarevsky SR. Influence of standard heart failure therapy on readmission rate: opportunities and limitations in modern clinical practice. Russ J Cardiol 2021;26:4699. [DOI: 10.15829/1560-4071-2021-4699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Logeart D, Berthelot E, Bihry N, Eschalier R, Salvat M, Garcon P, Eicher JC, Cohen A, Tartiere JM, Samadi A, Donal E, deGroote P, Mewton N, Mansencal N, Raphael P, Ghanem N, Seronde MF, Chavelas C, Rosamel Y, Beauvais F, Kevorkian JP, Diallo A, Vicaut E, Isnard R. Early and short-term intensive management after discharge for patients hospitalized with acute heart failure: a randomized study (ECAD-HF). Eur J Heart Fail 2021. [PMID: 34628697 DOI: 10.1002/ejhf.2357] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Iacoviello M, Vitale E, Corbo MD, Correale M, Brunetti ND. Disease-modifier Drugs in Patients with Advanced Heart Failure: How to Optimize Their Use? Heart Fail Clin 2021;17:561-73. [PMID: 34511205 DOI: 10.1016/j.hfc.2021.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Nessler J. Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction - a practical approach. Postepy Kardiol Interwencyjnej 2021;17:135-40. [PMID: 34400915 DOI: 10.5114/aic.2021.107491] [Reference Citation Analysis]
11 Dardano A, Daniele G, Penno G, Miccoli R, Del Prato S. Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report. Front Med (Lausanne) 2021;8:699477. [PMID: 34307425 DOI: 10.3389/fmed.2021.699477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, Adamopoulos S, Abdelhamid M, Bistola V, Čelutkienė J, Chioncel O, Farmakis D, Ferrari R, Filippatos G, Hill L, Jankowska EA, Jaarsma T, Jhund P, Lainscak M, Lopatin Y, Lund LH, Milicic D, Mullens W, Pinto F, Ponikowski P, Savarese G, Thum T, Volterrani M, Anker SD, Seferovic PM, Coats AJS. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2021;23:872-81. [PMID: 33932268 DOI: 10.1002/ejhf.2206] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 61.0] [Reference Citation Analysis]
13 Scalvini S, Bernocchi P, Villa S, Paganoni AM, La Rovere MT, Frigerio M. Treatment prescription, adherence, and persistence after the first hospitalization for heart failure: A population-based retrospective study on 100785 patients. Int J Cardiol 2021;330:106-11. [PMID: 33582198 DOI: 10.1016/j.ijcard.2021.02.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]